Time filter

Source Type

Southampton, United Kingdom

Johnson P.,University of Southampton | Johnson P.,Somers Cancer Research Building | McKenzie H.,University of Southampton
Blood | Year: 2015

The development of curative systemic treatment of Hodgkin lymphoma was recently voted one of the top 5 achievements of oncology in the last 50 years (http://cancerprogress. net/top-5-advances-modern-oncology). The high expectation of cure (above 80%) with initial therapy, even for advanced disease, is tempered by the recognition of some important limitations: not all patients are cured, especially those in older age groups, and patients have suffered debilitating or, in some cases, fatal long-term side effects. The challenge for modern treatment approaches is to improve the cure rate and, at the same time, minimize the long-term damage resulting from treatment. After several decades during which we have tested a variety of different ways to combine conventional cytotoxic treatments with or without radiotherapy but have identified no effective new approaches, the field is once again moving forward. The developments that hold the greatest promise in this respect are the application of functional imaging with 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) to make an early judgment of the success of treatment and the introduction of some highly active new agents such as antibody-drug conjugates. © 2015 by The American Society of Hematology. Source

Indolent non-Hodgkins lymphoma (iNHL) describes a group of B-cell lymphomas with a long median survival and a relapsing-remitting clinical course. Although existing treatments are initially effective, patients often relapse, demonstrating decreasing efficacy with successive treatment courses. Alternative treatments are needed. PI3Kδ plays an essential, non-redundant role in B-cell receptor signaling critical to the pathogenesis of iNHL. It is expressed predominantly in hematopoietic cells, making PI3Kδ an attractive therapeutic target. Idelalisib is an oral PI3Kδ inhibitor approved in 2014 in the USA and the EU as monotherapy in relapsed follicular lymphoma or relapsed small lymphocytic lymphoma previously treated with two or more prior systemic therapies, or as part of combination therapy with rituximab in patients with chronic lymphocytic leukemia, for whom rituximab monotherapy would be considered appropriate due to the presence of comorbidities. Herein, we review the available data for idelalisib, with an emphasis on relapsed/refractory B-cell iNHL. © 2015 © Informa UK, Ltd. Source

Doganay E.,Somers Cancer Research Building
Journal of Medical Biography | Year: 2015

The most acclaimed surgeon of his time, Astley Cooper, a man from Norfolk and a student of the eminent John Hunter, was an outstandingly successful surgeon. With his accomplishments in surgery and experiments in dissection he soon became a prominent figure and received recognition worldwide. At the young age of 21 he was appointed Demonstrator in Anatomy at St Thomas’s Hospital in London and two years later was made Joint Lecturer in Anatomy and Surgery. With his passion for anatomy, his love for surgery and his expanding knowledge he became Surgeon to Guy’s Hospital in 1800 and in the same year was elected a Fellow to the Royal Society. His attainments led him to become surgeon to three successive British monarchs as well as receiving a bestowal of Baronetcy. Through his edifying lectures, fastidious experiments and publications on anatomy and pathology he has inspired and enlightened many budding anatomists and surgeons and the principles of his teachings still prevail in practice today. © 2014, © The Author(s) 2014. Source

Discover hidden collaborations